Good morning, you're tuned in to Markets Desk.
Wall Street's long bull run may be approaching a reckoning. Private equity and buyout funds are sitting on roughly one point five trillion dollars in uninvested capital, and historical cycles suggest the window to deploy that dry powder productively is narrowing fast. Pressure to put money to work tends to drive valuations higher and discipline lower, which is worth watching closely.
Shifting to the regulatory front, Google has been handed a one billion dollar fine by European Union authorities, who found the company's dominance in search and advertising creates conditions that crowd out competition. The ruling demands structural changes that critics argue could paradoxically hurt the smaller publishers and advertisers who rely on Google's reach to build their own audiences. Brussels is drawing a hard line, and the tech sector is paying attention.
And on the pharma side, Pfizer's dividend yield has climbed to levels that typically signal investor doubt about sustainability, yet management is pushing back firmly on that narrative. The company points to its post-pandemic pipeline and cost restructuring as evidence the payout is well-supported, even as revenue from its covid franchise continues to normalize. The market remains skeptical, and that tension is worth monitoring into the next earnings cycle.
That's the tape. Markets Desk, signing off the floor.
